Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Trehalose for Vascular Inflammation in Acute Coronary Syndrome
NCT03700424Phase 2Unknown
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Aug 2020
- Primary completion
- May 2022
- Modality
- Drug Delivery Systems, DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute coronary syndrome (ACS) comparing Trehalose with Placebo (2 arms). Primary endpoint: Arterial wall inflammation in the aorta and carotid arteries at 12 weeks. Status: unknown.
02
Drugs
trehalose
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT03700424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03700424.